Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
Rattachement africain : us, cz, no, gb, it, be, dk, il. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Enzyme replacement therapies (ERTs) approved for Fabry disease require infusions every 2 weeks (E2W). Pegunigalsidase alfa, a PEGylated ERT with a prolonged half-life vs. other ERTs, may allow extension of the dosing interval to every 4 weeks (E4W). BRIGHT F51 (NCT03614234) is an ongoing phase III, open-label extension study evaluating long-term efficacy and safety of pegunigalsidase alfa 2 mg/kg E4W in adults with Fabry disease previously treated with agalsidase alfa or beta E2W for ≥ 3 years who completed one year of pegunigalsidase alfa treatment in the BRIGHT study. This interim analysis reports results following 3–5 years of treatment (cutoff date December 31, 2022). Results Twenty-nine patients were enrolled. Median (interquartile range [IQR]) annualized eGFR slope during treatment was ‒2.2 (‒2.9; ‒1.1) mL/min/1.73 m2/year (males: ‒2.4 [‒2.9; ‒1.0, n = 23]; females: ‒1.8 [‒2.4; ‒1.3, n = 6]; anti-drug antibody [ADA]-positive: ‒2.6 [‒4.0; ‒1.7, n = 9 all male]; ADA-negative: ‒1.8 [‒2.7; ‒0.6, n = 20]). Median (IQR) change in plasma lyso-Gb3 from baseline to Week 208 was 3.2 (‒3.9; 8.5, n = 17) nM in males; concentrations remained low and stable in females. Overall, 51/477 treatment-emergent adverse events in 13 patients (45%) were considered treatment-related (all mild/moderate). Nine patients (31%) experienced mild/moderate infusion-related reactions. One patient developed transient de novo ADAs. Conclusions Long-term treatment with pegunigalsidase alfa 2 mg/kg E4W was well-tolerated and maintained disease stability, especially in females and ADA-negative males; more data are needed to better understand outcomes in ADA-positive males. Clinical outcomes should be closely monitored during E4W treatment. The final results of this extension study will further assess the feasibility of this dosing regimen. Trial registration details ClinicalTrials.gov, NCT03614234. Registered July 30, 2018; https://clinicaltrials.gov/study/NCT03614234 . Graphical Abstract
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
Où se fait cette recherche
-
University of Iowa Health Care pays non établi dans la noticeÉtablissement de santé
-
Charles University pays non établi dans la noticeUniversité ou école supérieure
-
University of California pays non établi dans la noticeUniversité ou école supérieure
-
University of Alabama at Birmingham pays non établi dans la noticeUniversité ou école supérieure
-
Haukeland University Hospital pays non établi dans la noticeÉtablissement de santé
-
Royal Free London NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
University of Naples Federico II pays non établi dans la noticeUniversité ou école supérieure
-
Antwerp University Hospital pays non établi dans la noticeOrganisme public
-
Cambridge University Hospitals NHS Foundation Trust pays non établi dans la noticeOrganisme public
-
University of Copenhagen pays non établi dans la noticeUniversité ou école supérieure
-
Lysosomal and Rare Disorders Research and Treatment Center pays non établi dans la noticeInstitution
-
Baylor University Medical Center pays non établi dans la noticeÉtablissement de santé
University of Iowa Health Care, Charles University et University of California, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.